PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6313094

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
TJEERD BARF	04/28/2020
EDWIN DE ZWART	04/23/2020
SASKIA VERKAIK	04/23/2020
NIELS HOOGENBOOM	04/23/2020
DENNIS DEMONT	04/28/2020

RECEIVING PARTY DATA

Name:	ACERTA PHARMA B.V.
Street Address:	KLOOSTERSTRAAT 9
City:	OSS
State/Country:	NETHERLANDS
Postal Code:	5349 AB

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16917222

CORRESPONDENCE DATA

Fax Number: (215)963-5001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2159634890

Email: katie.kinsman@morganlewis.com

Correspondent Name: KATIE KINSMAN

Address Line 1: MORGAN, LEWIS & BOCKIUS, LLP

Address Line 2: 1701 MARKET STREET

Address Line 4: PHILADELPHIA, PENNSYLVANIA 19103

ATTORNEY DOCKET NUMBER:	055112-5059-US01
NAME OF SUBMITTER:	KATIE C. KINSMAN
SIGNATURE:	/Katie C. Kinsman/
DATE SIGNED:	09/23/2020
·	

Total Attachments: 3

PATENT REEL: 053856 FRAME: 0277 source=Executed Assignment#page1.tif
source=Executed Assignment#page2.tif
source=Executed Assignment#page3.tif

PATENT REEL: 053856 FRAME: 0278

<u>ASSIGNMENT</u>

WHEREAS, We,

Tjeerd Barf, a citizen of The Netherlands with a post office address of St. Luciastraat 7, 5371 AS, Ravenstein, The Netherlands

Edwin de Zwart, a citizen of The Netherlands with a post office address of Waaldijk 26, 6621 KH, Dreumel The Netherlands

Saskia Verkaik, a citizen of The Netherlands with a post office address of Caspar Boshartstraat 23, 5367 AC, Macharen, The Netherlands

Niels Hoogenboom, a citizen of The Netherlands with a post office address of Het Reut 605, 5351 TH Berghem, The Netherlands

Dennis Demont, a citizen of The Netherlands, With a post office address of Rietkraag 5, 5345 RS Oss The Netherlands

hereinafter generally referred to collectively as "<u>ASSIGNORS</u>," have invented certain new and useful inventions entitled:

Novel Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase

that is described in U.S. Provisional Application No. 62/252,420 filed November 6, 2015;

Novel Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase

That is described in U.S. Provisional Application No. 62/261,228 filed November 30, 2015;

Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase

That is described in International Patent Application No. PCT/IB2016/056661 filed November 4, 2016; &

Imidazopyrazine Inhibitors of Bruton's Tyrosine Kinase

That is described in U.S. Application No. 15/773,846 filed May 4, 2018;

hereinafter referred to as "Inventions" naming the above ASSIGNORS as inventors.

WHEREAS, Acerta Pharma B.V., a corporation of The Netherlands, having a place of business at Kloosterstraat 9, 5349 AB, Oss, The Netherlands, hereinafter generally referred to as "ASSIGNEE," is desirous of acquiring and/or confirming the acquisition of the Inventions.

DB1/ 89544867.1

1

PATENT REEL: 053856 FRAME: 0279 NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged and intending to be legally bound hereby, we, ASSIGNORS, have assigned and/or hereby sell, assign, transfer and convey unto ASSIGNEE, the whole and entire right, title and interest in and to:

all Inventions;

the above patent application[s] and any and all United States and foreign patent applications disclosing one or more of the Inventions including, without limitation, applications for patents including provisionals, non-provisionals, divisions, continuations, continuations-in-part, utility models, PCT applications and designs and any other related United States and foreign applications and equivalents thereof ("Applications"), along with the right to claim priority to the Applications under any treaty relating thereto;

all United States and foreign patents, utility models, inventor's certificates and designs and all equivalents thereof which may be granted for the Inventions or Applications, and all post-grant actions including extensions, renewals, reissues, reexamination certificates, post-grant review certificates, inter partes review certificates, and supplemental examination certificates thereof ("Patents"); and

all rights to sue for and collect damages resulting from past, present and future infringement of all granted or to be granted Patents.

The Inventions, Applications and Patents to be held and enjoyed by ASSIGNEE, for ASSIGNEE's own use and benefit, and for ASSIGNEE's legal representatives and assigns to the full end of the term or terms of said granted or to be granted Patents, as fully and entirely as the same would have been held by ASSIGNORS had this assignment and sale not been made; and for the aforesaid consideration ASSIGNORS hereby covenant, agree and undertake to execute, whenever requested by the above-named ASSIGNEE, all patent applications, assignments, declarations, lawful oaths and any other papers which ASSIGNEE may deem necessary or desirable for securing to ASSIGNEE or for maintaining for ASSIGNEE all the Inventions, Applications and Patents hereby assigned or agreed to be assigned; all without further compensation to the undersigned ASSIGNORS.

Each ASSIGNOR hereby represents and warrants that he/she has full right, power and authority to assign their entire right, title, and interest in the Patents, Applications, and Inventions, and to consummate the assignment contemplated herein. Each ASSIGNOR also represents and warrants that he/she has full right, power, and authority to enter into, execute, and deliver this Assignment, the execution and delivery of which have been duly authorized by all necessary action on the part of ASSIGNORS, and no other authorization or proceedings on the part of ASSIGNORS are necessary to authorize this Assignment. This Assignment has been duly executed and delivered and constitutes a valid, binding and enforceable assignment of the entire right, title, and interest in the Patents and Applications, and Inventions.

ASSIGNORS hereby warrant that no assignment, sale, agreement, or encumbrance has been or will be made or entered into which would conflict with this Assignment.

2

	[ASSIGNMENT MAY BE SIGNED IN COUNTERPARTS]
20-APR-2020 (Date)	Tjeerd Barf
23- <u>HPC-20</u> 80 (Date)	Edwin de Zwart
23 <i>-0<mark>001-202</mark>0</i> (Date)	Saskia Verkaik
23-1871-2026 (Date)	<u> </u>
00 8 70m	20

RECORDED: 09/23/2020